Improving the Bioavailability and Therapeutic Efficacy of Valsartan for the Control of Cardiotoxicity-Associated Breast Cancer
{{output}}
Cardiotoxicity remains the most severe side effect of breast cancer (BC) treatments. Valsartan, an angiotensin-II receptor blocker, has antioxidant properties that can mitigate cardiotoxicity-associated BC (CABC). However, valsartan's limited solubility and l... ...
